RAS, FLT3, and TP53 mutations in therapy‐related myeloid malignancies with abnormalities of chromosomes 5 and 7
暂无分享,去创建一个
R. Larson | M. L. Le Beau | K. Shannon | L. Side | C. Kratz | Nicole P Curtiss | K. Teel | Pauline W. Wang
[1] Sonali M. Smith,et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.
[2] J. Downing,et al. Acute leukemia: a pediatric perspective. , 2002, Cancer cell.
[3] Zhijian Qian,et al. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[4] G. Ehninger,et al. Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .
[5] D. Gilliland,et al. Focus on acute leukemias. , 2002, Cancer cell.
[6] Soyoung Lee,et al. A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy , 2002, Cell.
[7] S. Lowe,et al. Dissecting p53 tumor suppressor functions in vivo. , 2002, Cancer cell.
[8] M. Andersen,et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. , 2002, Blood.
[9] Gideon Bollag,et al. GTPase activating proteins: critical regulators of intracellular signaling. , 2002, Biochimica et biophysica acta.
[10] J. Downing,et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.
[11] D. Christiansen,et al. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy , 2001, Leukemia.
[12] E. Green,et al. Candidate gene isolation and comparative analysis of a commonly deleted segment of 7q22 implicated in myeloid malignancies. , 2001, Genomics.
[13] J. Radich,et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. , 2001, Blood.
[14] D. Christiansen,et al. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] N. Zhao,et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). , 2001, Genomics.
[16] W. Berdel,et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.
[17] S. Lowe,et al. Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.
[18] T. Naoe,et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.
[19] M. Taniwaki,et al. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype , 1999, Leukemia.
[20] M. Veigl,et al. Mice over-expressing human O6alkylguanine-DNA alkyltransferase selectively reduce O6methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea , 1999, Oncogene.
[21] T. Jacks,et al. Myeloid malignancies induced by alkylating agents in Nf1 mice. , 1999, Blood.
[22] T. Naoe,et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.
[23] T. Naoe,et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N‐ras and FLT3 genes compared with p53 gene , 1999, British journal of haematology.
[24] I. Weissman,et al. A PMLRARα transgene initiates murine acute promyelocytic leukemia , 1997 .
[25] S. Ben-Neriah,et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. , 1996, Blood.
[26] R. Larson,et al. Activating RAS mutations in therapy-related myeloid disorders associated with deletions of chromosomes 5 and 7. , 1996 .
[27] E. Green,et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. , 1996, Blood.
[28] T. Rabbitts,et al. An Mll–AF9 Fusion Gene Made by Homologous Recombination Causes Acute Leukemia in Chimeric Mice: A Method to Create Fusion Oncogenes , 1996, Cell.
[29] R. Larson,et al. Therapy-related myeloid leukemia. , 2008, Seminars in oncology.
[30] D. Largaespada,et al. Nf1 deficiency causes Ras-Dediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia , 1996, Nature Genetics.
[31] G. Mufti,et al. Possible co-existence of RAS activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes. , 1995, Leukemia research.
[32] T. Koh,et al. N-ras mutation in 7,12-dimethylbenz[a]anthracene (DMBA)-induced erythroleukemia in Long-Evans rats. , 1995, Cancer letters.
[33] E. Wattel,et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. , 1995, Leukemia.
[34] K. Shannon,et al. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras , 1994 .
[35] S. Gerson,et al. Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. , 1994, Cancer research.
[36] C. Denny,et al. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about , 1994, Cell.
[37] P. O'Connell,et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. , 1994, The New England journal of medicine.
[38] R. Espinosa,et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[39] S. Gerson,et al. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. , 1993, Science.
[40] C. Bloomfield,et al. ras oncogene activation and occupational exposures in acute myeloid leukemia. , 1992, Journal of the National Cancer Institute.
[41] P. O'Connell,et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. , 1992, Blood.
[42] R. Berger,et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. , 1991, Blood.
[43] K. Tanaka,et al. Cytogenetic and molecular changes in leukemia among atomic bomb survivors. , 1991, Journal of radiation research.
[44] E. Liu,et al. Mutations of the ras proto-oncogenes in childhood monosomy 7. , 1991, Blood.
[45] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[46] C. Bartram,et al. Point mutation of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents. , 1988, Cancer research.
[47] R. Larson,et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] J. Rowley,et al. Acute leukemia after treatment of lymphoma. , 1977, The New England journal of medicine.
[49] Jennifer Clark,et al. Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. , 2002, Current opinion in oncology.
[50] D. Gilliland,et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.
[51] J. Radich,et al. FLT 3 , RAS , and TP 53 mutations in elderly patients with acute myeloid leukemia , 2001 .
[52] 早川 文彦. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000 .
[53] I. Weissman,et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[54] J. Maris,et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. , 1997, Cancer.
[55] J. Pedersen‐Bjergaard. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. , 1992, Leukemia research.
[56] T. Sekiya,et al. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1990, Oncogene.